<html>
    <body><b>Bibliografía</b><br>
        <br>

         1.- Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., y Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. <i>Nature Reviews Drug Discovery</i>, <i>20</i>(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z<br>
         2.- Jha, R., y Zi-rong, X. (2004). Biomedical compounds from marine organisms. <i>Marine Drugs</i>, <i>2</i>(3), 123–146. https://doi.org/10.3390/md203123<br>
         3.- Blunt, J. W., Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., y Prinsep, M. R. (2018). Marine natural products. <i>Natural Product Reports</i>, <i>35</i>(1), 8–53. https://doi.org/10.1039/c7np00052a<br>
         4.- Ciavatta, M. L., Lefranc, F., Vieira, L. M., Kiss, R., Carbone, M., van Otterlo, W. A. L., Lopanik, N. B., y Waeschenbach, A. (2020). The phylum Bryozoa: From biology to biomedical potential. <i>Marine Drugs</i>, <i>18</i>(4), 200. https://doi.org/10.3390/md18040200<br>
         5.- Blackman, A. J., y Green, R. D. (1987). Further amathamide alkaloids from the Bryozoan Amathia wilsoni. <i>Australian Journal of Chemistry</i>, <i>40</i>(10), 1655–1662. https://doi.org/10.1071/ch9871655<br>
         6.- Khan, F. A., y Ahmad, S. (2012). Synthesis of reported and revised structures of Amathamide D and synthesis of Convolutamine F, H and Lutamide A, C. <i>The Journal of Organic Chemistry</i>, <i>77</i>(5), 2389–2397. https://doi.org/10.1021/jo3000173<br>
         7.- Ramírez-Osuna, M., Aguirre, G., Somanathan, R., y Molins, E. (2002). Asymmetric synthesis of amathamides A and B: novel alkaloids isolated from Amathia wilsoni. <i>Tetrahedron: Asymmetry</i>, <i>13</i>(20), 2261–2266. https://doi.org/10.1016/s0957-4166(02)00586-4<br>
         8.- Somanathan, R., Rivero, I. A., Aguirre, G., Ramirez, M., Hellberg, L. H., y Bakir, F. (1996). Synthesis of Tuberine. <i>Synthetic Communications</i>, <i>26</i>(5), 1023–1030. https://doi.org/10.1080/00397919608003707<br>
         9.- Ramírez-Osuna, M., Chávez, D., Medina Hernández, L., Molins, E., Somanathan, R., y Aguirre, G. (2005). Synthesis of analogs of Amathamide A and their preliminary antimicrobial activity. <i>Molecules</i>, <i>10</i>(1), 295–301. https://doi.org/10.3390/10010295<br>
        10.- Ramírez-Osuna, M., Narvaez-Garayzar, O. F., Somanathan, R., y Aguirre, G. (2011). Syntheses of three mono-brominated enamide analogs of natural alkaloids isolated from the Tasmanian marine Bryozoan Amathia Wilson. <i>Journal of the Mexican Chemical Society</i>, <i>55</i>(1), 57–61. https://doi.org/10.29356/jmcs.v55i1.852<br>
        11.- Beaulieu, J.-M., y Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. <i>Pharmacol. Rev.</i>, <i>63</i>, 182–217. https://doi.org/10.1124/pr.110.002642<br>
        12.- Perreault, M. L., Hasbi, A., O’Dowd, B. F., y George, S. R. (2014). Heteromeric dopamine receptor signaling complexes: Emerging neurobiology and disease relevance. <i>Neuropsychopharmacology</i>, <i>39</i>, 156–168. https://doi.org/10.1038/npp.2013.148<br>
        13.- Ryczko, D., y Dubuc, R. (2023). Dopamine control of downstream motor centers. <i>Curr. Opin. Neurobiol.</i>, <i>83</i>, 102785. https://doi.org/10.1016/j.conb.2023.102785<br>
        14.- Ott, T., y Nieder, A. (2019). Dopamine and cognitive control in prefrontal cortex. <i>Trends Cogn Sci</i>, <i>23</i>, 213–234. https://doi.org/10.1016/j.tics.2018.12.006<br>
        15.- Carr, G. V., Maltese, F., Sibley, D. R., Weinberger, D. R., y Papaleo, F. (2017). The dopamine D5 receptor is involved in working memory. <i>Front Pharmacol</i>, <i>8</i>, 666. https://doi.org/10.3389/fphar.2017.00666<br>
        16.- Martel, J. C., y Gatti McArthur, S. (2020). Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia. <i>Front Pharmacol</i>, <i>11</i>, 1003. https://doi.org/10.3389/fphar.2020.01003<br>
        17.- Mishra, A., Singh, S., y Shukla, S. (2018). Physiological and functional basis of dopamine receptors and their role in neurogenesis: Possible implication for Parkinson’s disease. <i>J Exp Neurosci</i>, <i>12</i>, 1179069518779829. https://doi.org/10.1177/1179069518779829<br>
        18.- Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., y Liu, A. (2019). Dopamine and dopamine receptors in Alzheimer’s disease: A systematic review and network meta-analysis. <i>Front Aging Neurosci</i>, <i>11</i>, 175. https://doi.org/10.3389/fnagi.2019.00175<br>
        19.- Wise, R. A., y Robble, M. A. (2020). Dopamine and addiction. <i>Annu Rev Psychol</i>, <i>71</i>, 79–106. https://doi.org/10.1146/annurev-psych-010418-103337<br>
        20.- Radwan, B., Liu, H., y Chaudhury, D. (2019). The role of dopamine in mood disorders and the associated changes in circadian rhythms and sleep-wake cycle. <i>Brain Res</i>, <i>1713</i>, 42–51. https://doi.org/10.1016/j.brainres.2018.11.031<br>
    </body>
</html>
